--- title: "Eloralintide | PepTracker Pro" url: https://peptrackerpro.com/peptides/eloralintide description: "A selective, long-acting amylin receptor agonist in Phase 3 trials for obesity, offering a GLP-1-independent weight loss mechanism with up to 20.1% weight loss in Phase 2." lang: en --- Skip to main content **Educational information only.** This site does not provide medical advice. Read full disclaimer (https://peptrackerpro.com/disclaimer) **Research-only content.** This page is for educational purposes and does not constitute medical advice. Read full disclaimer → (https://peptrackerpro.com/research-disclaimer) # Eloralintide Medium Evidence A selective, long-acting amylin receptor agonist in Phase 3 trials for obesity, offering a GLP-1-independent weight loss mechanism with up to 20.1% weight loss in Phase 2. Aliases LY3841136 Evidence Medium Evidence Last Updated 2026-06-14 Reading Time 3 min ## What It Is Eloralintide (LY3841136) is a novel, selective amylin receptor agonist developed by Eli Lilly for the treatment of obesity. Unlike GLP-1 receptor agonists, eloralintide works through a distinct amylin-based mechanism — amylin is a peptide hormone co-secreted with insulin that promotes satiety and slows gastric emptying. In a 48-week Phase 2 multicenter, double-blind, randomized, placebo-controlled trial published in The Lancet, all treatment arms met the primary endpoint, demonstrating dose-dependent weight reductions from 9.5% to 20.1% compared to 0.4% with placebo. Notably, eloralintide demonstrated 11.3% additional weight loss when added to tirzepatide therapy, suggesting strong combination potential. The safety profile was favorable, with mild-to-moderate gastrointestinal events and fatigue as the most common adverse effects. Lilly's Phase 3 clinical studies are actively enrolling, and a Phase 2 combination trial with CT-388 is underway. The Phase 1 proof-of-concept study was formally published in Diabetes, Obesity and Metabolism (Bhattachar et al., 2026), confirming selective amylin receptor engagement and dose-proportional pharmacokinetics that support the ongoing Phase 3 program. Eloralintide represents a new drug class for obesity — selective amylin agonists — distinct from the GLP-1 and GIP agonists that currently dominate the market, and its combination potential may set a new efficacy ceiling for metabolic therapies. June 2026 update: following the ADA 2026 Scientific Sessions (June 5–8, New Orleans), eloralintide is increasingly viewed as the lead asset validating selective amylin agonism as a standalone obesity mechanism. Eli Lilly is running a dedicated Phase 2 trial of eloralintide alone and in combination with tirzepatide (NCT06916065), with analysts expecting combination data in late 2026, and the company has stated Phase 3 enrollment for eloralintide monotherapy will begin by the end of 2026. Industry analysts highlight eloralintide's notably milder gastrointestinal side-effect profile versus GLP-1 receptor agonists as its key differentiator — positioning it both as an alternative for GI-intolerant patients and as a 'reusable building block' in Lilly's combination strategy alongside tirzepatide and retatrutide. Also known as: LY3841136 ## Regulatory Status Investigational Phase 3 clinical trials enrolling as of late 2025. Not yet approved in any jurisdiction. Effective: 2025 View FDA Source (https://clinicaltrials.gov/study/NCT07282600) ## Why Researchers Study It Eloralintide represents a new class of obesity therapeutics — selective amylin receptor agonists — offering a GLP-1-independent mechanism. Its distinct pathway makes it a prime candidate for combination therapy with GLP-1 agonists, potentially achieving greater weight loss than either mechanism alone. The amylin pathway's role in satiety signaling and gastric emptying is complementary to GLP-1 effects. ## Proposed Mechanisms - Selectively activates amylin receptors (calcitonin receptor + RAMP complexes) in the area postrema and hypothalamus - Promotes satiety through central appetite suppression via amylin signaling - Slows gastric emptying to prolong post-meal fullness - Does not directly engage GLP-1, GIP, or glucagon receptors — independent mechanism of action - Long-acting design enables once-weekly subcutaneous dosing ## Evidence Snapshot Medium Evidence Low Medium High | Study Type | Model | Outcome | Link | | --- | --- | --- | --- | | Human (Phase 2) | Adults with obesity, 48-week, multicenter, double-blind, placebo-controlled (Lancet 2025) | Dose-dependent weight loss: 9.5% to 20.1% vs 0.4% placebo; all arms met primary endpoint | Source: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02155-5/abstract | | Human (Phase 1) | Proof of concept study | Demonstrated target engagement and dose-proportional pharmacokinetics | Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC12992164/ | | Human (Phase 1, peer-reviewed) | Phase 1 proof-of-concept, published in Diabetes, Obesity and Metabolism (Bhattachar et al., 2026) | Selective amylin receptor agonism confirmed with dose-proportional pharmacokinetics and a tolerability profile supporting once-weekly dosing; underpins ongoing Phase 3 program | Source: https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.70439 | | Human (Phase 2, ongoing) | Eloralintide alone and in combination with tirzepatide in adults with overweight or obesity (NCT06916065) | Ongoing; combination readout expected late 2026. Phase 2 monotherapy previously showed 11.3% additional weight loss when added to tirzepatide | Source: https://clinicaltrials.gov/study/NCT06916065 | ## Commonly Discussed Benefits Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Researching Eloralintide? Track it, set reminders, and keep notes in the free app. Track in App (https://app.peptrackerpro.com/?add=eloralintide) ## Safety & Cautions - Phase 3 trials ongoing; not yet FDA-approved - Higher GI side effects and fatigue reported at higher doses - Long-term safety and efficacy data from Phase 3 trials not yet available - Only available through clinical trial enrollment - Combination therapy data (with CT-388) still pending - Eloralintide + tirzepatide combination readout (NCT06916065) expected late 2026; Phase 3 monotherapy enrollment begins by end of 2026 - An oral small-molecule amylin agonist (ACCG-2671) entered first-in-human testing in December 2025, signaling a move toward pill-based amylin therapy alongside injectable amylin peptides like eloralintide. ## Comparisons See how Eloralintide compares to related peptides: Eloralintide vs ACCG-2671: https://peptrackerpro.com/compare/eloralintide-vs-accg-2671 Eloralintide vs ALV-200: https://peptrackerpro.com/compare/eloralintide-vs-alv-200 Eloralintide vs ASC39: https://peptrackerpro.com/compare/eloralintide-vs-asc39 Eloralintide vs Cagrilintide: https://peptrackerpro.com/compare/eloralintide-vs-cagrilintide Eloralintide vs MET-233i: https://peptrackerpro.com/compare/eloralintide-vs-met-233i Eloralintide vs Retatrutide: https://peptrackerpro.com/compare/eloralintide-vs-retatrutide Eloralintide vs Semaglutide: https://peptrackerpro.com/compare/eloralintide-vs-semaglutide Eloralintide vs Tirzepatide: https://peptrackerpro.com/compare/eloralintide-vs-tirzepatide Eloralintide vs AZD6234: https://peptrackerpro.com/compare/eloralintide-vs-azd6234 ## Calculator Tools Use our research tools to explore dosing and reconstitution data: Reconstitution Calculator: https://peptrackerpro.com/calculators ## Citations 1. [1] Eloralintide Phase 2 trial — Lancet 2025 PubMed (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)02155-5/abstract) 2. [2] Eli Lilly — Eloralintide Phase 2 results press release PubMed (https://lilly.gcs-web.com/news-releases/news-release-details/lillys-selective-amylin-agonist-eloralintide-demonstrated) 3. [3] Eloralintide Phase 1 proof of concept — PMC PubMed (https://pmc.ncbi.nlm.nih.gov/articles/PMC12992164/) 4. [4] Bhattachar SN. et al. — Eloralintide, a selective long-acting amylin receptor agonist: Phase 1 proof of concept (DOM 2026) PubMed (https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.70439) 5. [5] ClinicalTrials.gov — Eloralintide and Eloralintide With Tirzepatide in Overweight or Obesity (NCT06916065) PubMed (https://clinicaltrials.gov/study/NCT06916065) 6. [6] BioSpace — Obesity Space Abuzz With Oral, Amylin Assets as Momentum Rides Into 2026 PubMed (https://www.biospace.com/drug-development/obesity-space-abuzz-with-oral-amylin-assets-as-momentum-rides-into-2026) 7. [7] Eli Lilly — What to know about eloralintide PubMed (https://www.lilly.com/news/stories/what-to-know-about-eloralintide) ### Keep researching in the app - Log Eloralintide to your private tracker - Set a dosing reminder - Compare it side-by-side with your stack Open PepTracker Pro Free: https://app.peptrackerpro.com/?add=eloralintide Browse more peptides: https://peptrackerpro.com/peptides ## Related Peptides ### ACCG-2671 Low Evidence An oral, once-daily small-molecule amylin receptor agonist in first-in-human Phase 1 testing for obesity — an early entrant in the race to make amylin biology available as a pill rather than an injection. Fat Loss: https://peptrackerpro.com/benefits/fat-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/accg-2671 \+ Compare: https://peptrackerpro.com/compare?select=accg-2671 Track in App: https://app.peptrackerpro.com/?add=accg-2671 ### ALV-200 Low Evidence ALV-200 is Alveus Therapeutics' highly selective amylin receptor 3 (AMYR3) peptide agonist in IND-enabling development for obesity, designed to capture amylin's weight-loss and lean-mass-preserving benefits while avoiding the nausea and aversion tied to calcitonin-receptor activation. It is engineered for once-weekly dosing. Weight Management: https://peptrackerpro.com/benefits/weight-management Metabolism: https://peptrackerpro.com/benefits/metabolism Fat Loss: https://peptrackerpro.com/benefits/fat-loss Muscle Preservation: https://peptrackerpro.com/benefits/muscle-preservation View Details: https://peptrackerpro.com/peptides/alv-200 \+ Compare: https://peptrackerpro.com/compare?select=alv-200 Track in App: https://app.peptrackerpro.com/?add=alv-200 ### ASC39 Low Evidence ASC39 is Ascletis Pharma's investigational once-daily oral small-molecule amylin-selective amylin receptor agonist for obesity. In head-to-head preclinical assays it matched Eli Lilly's injectable peptide eloralintide on amylin-receptor potency, selectivity over the calcitonin receptor, and weight loss in diet-induced obese rats. Ascletis plans to file a U.S. FDA IND for ASC39 - and for a fixed-dose combination with its oral GLP-1 agonist ASC30 - in the third quarter of 2026. View Details: https://peptrackerpro.com/peptides/asc39 \+ Compare: https://peptrackerpro.com/compare?select=asc39 Track in App: https://app.peptrackerpro.com/?add=asc39 ### Cagrilintide High Evidence A long-acting amylin analog studied for appetite regulation; NDA filed for CagriSema (cagrilintide + semaglutide) combination in December 2025, with FDA review expected in 2026. Weight Management: https://peptrackerpro.com/benefits/weight-management Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation Metabolism: https://peptrackerpro.com/benefits/metabolism View Details: https://peptrackerpro.com/peptides/cagrilintide \+ Compare: https://peptrackerpro.com/compare?select=cagrilintide Track in App: https://app.peptrackerpro.com/?add=cagrilintide ### MET-233i Medium Evidence MET-233i is a first-in-class, once-monthly ultra-long-acting amylin analog for obesity, originally developed by Metsera and now a Pfizer asset. In its Phase 1 trial it produced up to 8.4% placebo-subtracted weight loss after five weekly doses and showed a roughly 19-day half-life - the most durable of any reported amylin analog - supporting once-monthly subcutaneous dosing. It is engineered to be combined with Metsera's monthly GLP-1 agonist MET-097i in a single once-monthly injection. View Details: https://peptrackerpro.com/peptides/met-233i \+ Compare: https://peptrackerpro.com/compare?select=met-233i Track in App: https://app.peptrackerpro.com/?add=met-233i ### Retatrutide High Evidence An investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease. View Details: https://peptrackerpro.com/peptides/retatrutide \+ Compare: https://peptrackerpro.com/compare?select=retatrutide Track in App: https://app.peptrackerpro.com/?add=retatrutide ### Semaglutide High Evidence A GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+3 more View Details: https://peptrackerpro.com/peptides/semaglutide \+ Compare: https://peptrackerpro.com/compare?select=semaglutide Track in App: https://app.peptrackerpro.com/?add=semaglutide ### Tirzepatide High Evidence A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis. Weight Management (https://peptrackerpro.com/benefits/weight-management)Appetite Regulation (https://peptrackerpro.com/benefits/appetite-regulation)Metabolism (https://peptrackerpro.com/benefits/metabolism)Fat Loss (https://peptrackerpro.com/benefits/fat-loss)+1 more View Details: https://peptrackerpro.com/peptides/tirzepatide \+ Compare: https://peptrackerpro.com/compare?select=tirzepatide Track in App: https://app.peptrackerpro.com/?add=tirzepatide ### AZD6234 Medium Evidence AZD6234 is an investigational, long-acting selective amylin receptor agonist (SARA) from AstraZeneca, given once weekly by subcutaneous injection and developed for chronic weight management in adults with obesity or overweight. Amylin is a natural pancreatic hormone that works alongside insulin to signal fullness, slow stomach emptying and reduce food intake, and a wave of amylin-based drugs is being pursued as a better-tolerated alternative or partner to GLP-1 medicines such as semaglutide and tirzepatide. AZD6234 is engineered as a synthetic long-acting pramlintide analog whose balance of activity at the amylin receptor (AMY3R) versus the calcitonin receptor is tuned to mimic native amylin, and in animal studies it produced fat-selective weight loss while sparing lean mass and showed less nausea/aversion signaling than some rival approaches. It is now in Phase 2, including a factorial obesity study testing AZD6234 alone, AstraZeneca's GLP-1/glucagon dual agonist AZD9550 alone, and the two combined, versus placebo. AZD6234 is not approved by the FDA or any regulator for any use. weight-loss: https://peptrackerpro.com/benefits/weight-loss Appetite Regulation: https://peptrackerpro.com/benefits/appetite-regulation metabolic-health: https://peptrackerpro.com/benefits/metabolic-health View Details: https://peptrackerpro.com/peptides/azd6234 \+ Compare: https://peptrackerpro.com/compare?select=azd6234 Track in App: https://app.peptrackerpro.com/?add=azd6234 ## Structured data ```json [ { "@context": "https://schema.org", "@type": "Organization", "name": "PepTracker Pro", "url": "https://peptrackerpro.com", "logo": "https://peptrackerpro.com/favicon.png", "description": "Evidence-based educational resource dedicated to improving peptide research literacy.", "contactPoint": { "@type": "ContactPoint", "email": "hello@peptrackerpro.com", "contactType": "customer support" }, "sameAs": [] }, { "@context": "https://schema.org", "@type": "MedicalWebPage", "name": "Eloralintide", "description": "A selective, long-acting amylin receptor agonist in Phase 3 trials for obesity, offering a GLP-1-independent weight loss mechanism with up to 20.1% weight loss in Phase 2.", "url": "https://peptrackerpro.com/peptides/eloralintide", "lastReviewed": "2026-06-14", "reviewedBy": { "@type": "Organization", "name": "PepTracker Pro Research Team", "url": "https://peptrackerpro.com" }, "isPartOf": { "@type": "WebSite", "name": "PepTracker Pro", "url": "https://peptrackerpro.com" } }, { "@context": "https://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "Home", "item": "https://peptrackerpro.com" }, { "@type": "ListItem", "position": 2, "name": "Peptides", "item": "https://peptrackerpro.com/peptides" }, { "@type": "ListItem", "position": 3, "name": "Eloralintide", "item": "https://peptrackerpro.com/peptides/eloralintide" } ] }, { "@context": "https://schema.org", "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "People exploring non-GLP-1 weight loss mechanisms?", "acceptedAnswer": { "@type": "Answer", "text": "Eloralintide is a research peptide studied in preclinical models. A selective, long-acting amylin receptor agonist in Phase 3 trials for obesity, offering a GLP-1-independent weight loss mechanism with up to 20.1% weight loss in Phase 2." } }, { "@type": "Question", "name": "Those interested in amylin-based obesity treatments?", "acceptedAnswer": { "@type": "Answer", "text": "Eloralintide is a research peptide studied in preclinical models. A selective, long-acting amylin receptor agonist in Phase 3 trials for obesity, offering a GLP-1-independent weight loss mechanism with up to 20.1% weight loss in Phase 2." } }, { "@type": "Question", "name": "Individuals following Eli Lilly's obesity pipeline?", "acceptedAnswer": { "@type": "Answer", "text": "Eloralintide is a research peptide studied in preclinical models. A selective, long-acting amylin receptor agonist in Phase 3 trials for obesity, offering a GLP-1-independent weight loss mechanism with up to 20.1% weight loss in Phase 2." } }, { "@type": "Question", "name": "Healthcare providers evaluating combination therapy strategies?", "acceptedAnswer": { "@type": "Answer", "text": "Eloralintide is a research peptide studied in preclinical models. A selective, long-acting amylin receptor agonist in Phase 3 trials for obesity, offering a GLP-1-independent weight loss mechanism with up to 20.1% weight loss in Phase 2." } } ] } ] ```